World-class
Scientific Advisory

Work with Richmond Pharmacology and trust your experience will be personal and truly strategic.

Keith Berelowitz, MSc
Director of Operations

A scientist by training, Keith has worked in clinical research (academic and commercial) for over 22 years, having spent the majority of that period working for Richmond Pharmacology. In his role as Director of Operations at Richmond Pharmacology he is focused on the commercial management of the studies we conduct, the efficiency of the company’s functions and oversight of the healthy volunteer and patient recruitment division, integral to the studies conducted by Richmond Pharmacology.

Having played an operational role in over 250 studies, across the commercial, project and recruitment related management of these studies, his specialist area of interest has focused on the assessment and delivery of early and late phase patient trials in a Phase I environment. Keith has worked with a number of sponsors advising them on the viability of conducting such trials within the UK, a number of which have gone on to be conducted successfully with Richmond Pharmacology.

Keith is a member of the National Research Ethics Service Phase 1 Advisory Group (Health Research Authority, UK), Vice Chair of the Fulham Research Ethics Committee and a member of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI, UK) and one of the UK representative of the EUCROF Extended Executive Board

Back to experts

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more